Clinical characteristics of cadonilimab-associated infusion reactions: a severity-stratified analysis of 52 cases and preliminary management framework
4 affiliations
- 1Department of Pharmacy, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University
- 2Department of Pharmacy, The People’s Hospital of Jianyang City
- 3Department of Clinical Pharmacy, Yantai Traditional Chinese Medicine Hospital
- 4Department of Gastroenterology and Urology, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University
Abstract
Objective: To describe the clinical characteristics of infusion-related reactions (IRRs) associated with cadonilimab in a real-world cohort and propose preliminary management considerations based on these observations.
Methods: A descriptive retrospective case series was conducted, involving data collection from 52 patients who received cadonilimab and subsequently experienced infusion-related reactions at a tertiary hospital between July 2022 and December 2025. Patients were classified into a common IRR group (n=31) and a severe IRR group (n=21) based on the severity criteria outlined in CTCAE 6.0. We conducted a comparative analysis of baseline characteristics, IRR onset timing, clinical manifestations, management strategies, and outcomes between the two groups.
Results: The median time to IRR onset was 20 minutes post-infusion, with the highest proportion of recorded IRR cases occurring during the second treatment cycle (42.3%). Severe IRR manifested as multi-organ involvement in 61.9% of cases, predominantly affecting the respiratory and cardiovascular systems. Patients with severe IRR more frequently received corticosteroids combined with antihistamines (57.1% vs. 29.0%) and had higher rates of premedication (76.2% vs. 45.2%). Twenty-four patients (46.2%) attempted same-cycle infusion resumption; among these, 15 (62.5%) successfully completed the infusion without symptom recurrence. Among the 10 severe-group patients who attempted same-cycle infusion resumption, 6 (60.0%) experienced recurrent symptoms; among all 21 severe-group patients, the recurrence rate was 28.6% (6/21). The clinically relevant same-cycle recurrence rates were 9/24 overall (37.5%), 3/14 (21.4%) in the common group, and 6/10 (60.0%) in the severe group.
Conclusion: Cadonilimab is associated with early-onset infusion-related reactions frequently involving multiple organ systems. Based on our institutional experience, we propose a preliminary management framework that requires prospective validation before it can be recommended for routine clinical practice.
Related
- Clinical characteristics and preliminary discriminatory value of low triiodothyronine syndrome in patients with peritoneal dialysis-associated peritonitis : A cross-sectional study
- Case Report: Severe multi-organ damage induced by cadonilimab: mechanism investigation and management strategies
- Clinical characteristics, management, and outcomes of nivolumab-associated pituitary toxicity: a pooled analysis of published case reports and case series
- Evolution of treatment strategies and risk-stratified management of patent ductus arteriosus in preterm infants
- Cadonilimab plus gemcitabine and cisplatin as first-line treatment for unresectable locally advanced or metastatic biliary tract malignancies: the phase II bicureX clinical trial
BibTeX
@article{li2026clinical,
title = {{Clinical characteristics of cadonilimab-associated infusion reactions: a severity-stratified analysis of 52 cases and preliminary management framework}},
author = {Jinlan Li and Rui Qiu and Guisen Yin and Yong Pan and Po Chen},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1815365},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1815365/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Clinical characteristics of cadonilimab-associated infusion reactions: a severity-stratified analysis of 52 cases and preliminary management framework
AU - Jinlan Li
AU - Rui Qiu
AU - Guisen Yin
AU - Yong Pan
AU - Po Chen
PY - 2026
DA - 2026/10/09
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1815365
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1815365/full
AB - Objective: To describe the clinical characteristics of infusion-related reactions (IRRs) associated with cadonilimab in a real-world cohort and propose preliminary management considerations based on these observations. Methods: A descriptive retrospective case series was conducted, involving data collection from 52 patients who received cadonilimab and subsequently experienced infusion-related reactions at a tertiary hospital between July 2022 and December 2025. Patients were classified into a common IRR group (n=31) and a severe IRR group (n=21) based on the severity criteria outlined in CTCAE 6.0. We conducted a comparative analysis of baseline characteristics, IRR onset timing, clinical manifestations, management strategies, and outcomes between the two groups. Results: The median time to IRR onset was 20 minutes post-infusion, with the highest proportion of recorded IRR cases occurring during the second treatment cycle (42.3%). Severe IRR manifested as multi-organ involvement in 61.9% of cases, predominantly affecting the respiratory and cardiovascular systems. Patients with severe IRR more frequently received corticosteroids combined with antihistamines (57.1% vs. 29.0%) and had higher rates of premedication (76.2% vs. 45.2%). Twenty-four patients (46.2%) attempted same-cycle infusion resumption; among these, 15 (62.5%) successfully completed the infusion without symptom recurrence. Among the 10 severe-group patients who attempted same-cycle infusion resumption, 6 (60.0%) experienced recurrent symptoms; among all 21 severe-group patients, the recurrence rate was 28.6% (6/21). The clinically relevant same-cycle recurrence rates were 9/24 overall (37.5%), 3/14 (21.4%) in the common group, and 6/10 (60.0%) in the severe group. Conclusion: Cadonilimab is associated with early-onset infusion-related reactions frequently involving multiple organ systems. Based on our institutional experience, we propose a preliminary management framework that requires prospective validation before it can be recommended for routine clinical practice.
SN - 1664-3224
ER -